Teva Pharma (TEVA) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Mizuho Securities Cuts Price Target on Teva Pharma (TEVA) Following Slight 4Q EPS Miss
February 12, 2016 7:33 AM ESTMizuho Securities reiterated a Buy rating on Teva Pharma (NYSE: TEVA), and cut the price target to $78.00 (from $79.00), following the company's 4Q earnings report. Teva reported a modest beat on revenues of $4.88B relative to consensus estimates of $4.84B, but missed bottom-line by a... More
